結核検査市場：検査項目、適応症、検査場所、エンドユーザー別-2025-2030年の世界予測

結核検査市場は、2023年に22億5,000万米ドルと評価され、2024年には23億8,000万米ドルに達すると予測され、CAGR 5.88％で成長し、2030年には33億6,000万米ドルに達すると予測されています。

結核検査市場には、皮膚検査、血液検査、顕微鏡検査、核酸検査、培養ベース検査など、結核感染の検出に使用されるさまざまな診断検査が含まれます。これらの検査は、活動性結核症例や潜在性結核感染の特定に極めて重要であり、この伝染病の蔓延を抑制するのに役立ちます。結核検査の必要性は、蔓延地域と非蔓延地域の両方において、トランスミッションを抑制し、的を絞った治療を提供するために適用されることにあります。結核検査は、病院、診療所、診断研究所などのヘルスケア環境において不可欠であり、公衆衛生の向上を目指す保健省や政府に貢献しています。この市場を牽引しているのは、罹患率の増加、早期かつ正確な診断に対するニーズの高まり、検査精度とスピードの進歩です。この分野における最新の潜在的なビジネスチャンスの1つは、検査解釈のためのデジタルヘルス技術とAIの統合から生じ、迅速な診断と患者管理の改善につながる可能性があります。市場成長は、結核撲滅に向けた政府の取り組み、認知度の向上とスクリーニング・プログラム、研究開発資金の増加といった要因に影響されます。制限事項としては、特に高度な分子検査にかかるコストの高さ、低資源環境におけるインフラの課題、熟練者の必要性などが挙げられます。課題としては、結核感染の潜伏性という性質が、タイムリーな診断と公衆衛生上の対応を複雑にしていることが挙げられます。技術革新のための最良の分野は、遠隔地や十分なサービスを受けていない地域でも実施可能な、よりアクセスしやすく費用対効果の高いポイントオブケア検査の開発です。これには、簡易検査キットや移動式検査ユニットなどが含まれます。ワクチン開発の調査もまた、技術革新のための肥沃な土地です。市場は、検査インフラやアウトリーチ・プログラムを強化するための公衆衛生機関と民間企業とのパートナーシップの増加とともに適応しつつあり、チャンスと課題の両方が熟したダイナミックな分野となっています。

市場力学：急速に進化する結核検査市場の主要市場インサイトを公開

結核検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の結核有病率の上昇
  • 政府および規制当局による結核に対する認識および管理プログラムの高まり
  • ポイントオブケアの高い可能性結核検査
• 市場抑制要因
  • 高度な結核検査にかかるコストの高さ
• 市場機会
  • より迅速な診断を可能にする診断技術の継続的開発
  • 高度な設備を備えた結核診断センターの増加
• 市場の課題
  • 結核検査の実施と解釈に熟練したヘルスケア専門家

ポーターの5つの力：結核検査市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：結核検査市場における外部からの影響の把握

外部マクロ環境要因は、結核検査市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析結核検査市場における競合情勢の把握

結核検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス結核検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、結核検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨結核検査市場における成功への道筋を描く

結核検査市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で結核の罹患率が上昇
    • 政府および規制当局による結核啓発および管理プログラムの拡大
    • ポイントオブケアの高い可能性結核検査
  • 抑制要因
    • 高度な結核検査の高コスト
  • 機会
    • より迅速な診断を可能にする診断技術の継続的な開発
    • 先進的な設備を備えた結核診断センターの増加
  • 課題
    • 結核検査の実施と解釈に精通した熟練したヘルスケア専門家
• 市場セグメンテーション分析
  • 検査：非侵襲性と有効性により、潜在性結核感染の診断におけるIGRAの使用が増加している
  • エンドユーザー：政府や公衆衛生機関を通じて結核検査に容易にアクセスできるようにし、結核の蔓延を抑制し、公衆衛生の目標を達成する
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 結核検査市場テスト別

• 文化に基づくテスト
• インターフェロン-ガンマ放出アッセイ
• マントーツベルクリン皮膚テスト
• 核酸増幅検査
• 塗抹顕微鏡検査

第7章 結核検査市場適応症別

• 活動性結核感染症
• 潜在性結核感染

第8章 結核検査市場試験場所別

• 実験室内試験
• ポイントオブケア検査

第9章 結核検査市場：エンドユーザー別

• 診断検査室
• 政府および公衆衛生機関
• 病院
• 調査・学術機関

第10章 南北アメリカの結核検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の結核検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの結核検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • Revvityが結核検査の高度な自動化を導入し、効率と精度を向上
  • MedGenomeはDarshan GIVA財団と協力し、全ゲノム配列解析を通じて結核診断を強化します
  • VinBrain、結核撲滅のためベトナムの国家結核スクリーニングイニシアチブと提携
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Becton, Dickinson, and Company
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Bruker Corporation
• Cepheid by Danaher Corporation
• Elisabeth Pharmacon, spol. s r.o.
• ELITech Group SAS
• F. Hoffmann-La Roche AG
• Fujifilm Holdings Corporation
• Hologic Corporation
• Lionex Diagnostics & Therapeutics GmbH
• OSANG HEALTHCARE CO., LTD
• PerkinElmer, Inc.
• SD Biosensor, INC.
• Siemens AG
• Thermo Fisher Scientific, Inc.
• Trivitron Healthcare Private Limited
• Tulip Diagnostics（P）Ltd
• Turklab A.S.

LIST OF FIGURES

• FIGURE 1. TUBERCULOSIS TESTING MARKET RESEARCH PROCESS
• FIGURE 2. TUBERCULOSIS TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. TUBERCULOSIS TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. TUBERCULOSIS TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. TUBERCULOSIS TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. TUBERCULOSIS TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE-BASED TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY INTERFERON-GAMMA RELEASE ASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MANTOUX TUBERCULIN SKIN TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SMEAR MICROSCOPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ACTIVE TB INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATENT TB INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IN-LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 37. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 38. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 39. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 40. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 59. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 60. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 61. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 62. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 64. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 66. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 132. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 133. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 134. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 135. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 148. POLAND TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 149. POLAND TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 150. POLAND TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 151. POLAND TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 152. QATAR TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 153. QATAR TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 154. QATAR TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 155. QATAR TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 192. TUBERCULOSIS TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 193. TUBERCULOSIS TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Tuberculosis Testing Market was valued at USD 2.25 billion in 2023, expected to reach USD 2.38 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 3.36 billion by 2030.

The scope of the Tuberculosis (TB) Testing market encompasses various diagnostic tests used to detect TB infections, including skin tests, blood tests, microscopy, nucleic acid tests, and culture-based tests. These tests are crucial in identifying active TB cases and latent TB infections, which aids in controlling the spread of this contagious disease. The necessity of TB testing lies in its application in both endemic and non-endemic regions to curb transmission and provide targeted treatment. They are essential in healthcare settings such as hospitals, clinics, and diagnostic laboratories, serving health departments and governments aiming for public health advancement. The market is driven by increasing incidence rates, a rising need for early and precise diagnostics, and advancements in test accuracy and speed. One of the latest potential opportunities within this sector arises from the integration of digital health technologies and AI for test interpretation, which can lead to quicker diagnosis and improved patient management. Market growth is influenced by factors such as government initiatives for TB eradication, rising awareness and screening programs, and increasing funding for R&D. Limitations include high costs, especially for advanced molecular tests, infrastructural challenges in low-resource settings, and the requirement for skilled personnel. A challenging factor is the latent nature of TB infections, which complicates timely diagnosis and public health responses. The best areas for innovation touch upon developing more accessible, cost-effective point-of-care tests that can be implemented in remote or underserved areas. This could include simplified test kits or mobile testing units. Research into vaccine development also represents a fertile ground for innovation. The market is adapting with an increase in partnerships between public health bodies and private enterprises to enhance testing infrastructure and outreach programs, making it a dynamic field ripe with both opportunities and challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Tuberculosis Testing Market

The Tuberculosis Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rise in the prevalence of tuberculosis worldwide
  • Growing tuberculosis awareness and control programs by government and regulatory authorities
  • High potential of point-of-care tuberculosis testing
• Market Restraints
  • High cost of advanced tuberculosis testings
• Market Opportunities
  • Ongoing developments in diagnostic technologies that enable faster diagnosis
  • Increasing number of tuberculosis diagnostic centers with advanced facilities
• Market Challenges
  • Skilled healthcare professionals proficient in administering and interpreting TB tests

Porter's Five Forces: A Strategic Tool for Navigating the Tuberculosis Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Tuberculosis Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Tuberculosis Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Tuberculosis Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Tuberculosis Testing Market

A detailed market share analysis in the Tuberculosis Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Tuberculosis Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Tuberculosis Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Tuberculosis Testing Market

A strategic analysis of the Tuberculosis Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Tuberculosis Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Bruker Corporation, Cepheid by Danaher Corporation, Elisabeth Pharmacon, spol. s r.o., ELITech Group SAS, F. Hoffmann-La Roche AG, Fujifilm Holdings Corporation, Hologic Corporation, Lionex Diagnostics & Therapeutics GmbH, OSANG HEALTHCARE CO., LTD, PerkinElmer, Inc., SD Biosensor, INC., Siemens AG, Thermo Fisher Scientific, Inc., Trivitron Healthcare Private Limited, Tulip Diagnostics (P) Ltd, and Turklab A.S..

Market Segmentation & Coverage

This research report categorizes the Tuberculosis Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Test, market is studied across Culture-Based Tests, Interferon-Gamma Release Assays, Mantoux Tuberculin Skin Test, Nucleic Acid Amplification Tests, and Smear Microscopy.
• Based on Indication, market is studied across Active TB Infection and Latent TB Infection.
• Based on Testing Location, market is studied across In-laboratory Testing and Point-of-Care Testing.
• Based on End User, market is studied across Diagnostic Laboratories, Government & Public Health Organizations, Hospital, and Research & Academic Institutions.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in the prevalence of tuberculosis worldwide
    • 5.1.1.2. Growing tuberculosis awareness and control programs by government and regulatory authorities
    • 5.1.1.3. High potential of point-of-care tuberculosis testing
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of advanced tuberculosis testings
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing developments in diagnostic technologies that enable faster diagnosis
    • 5.1.3.2. Increasing number of tuberculosis diagnostic centers with advanced facilities
  • 5.1.4. Challenges
    • 5.1.4.1. Skilled healthcare professionals proficient in administering and interpreting TB tests
• 5.2. Market Segmentation Analysis
  • 5.2.1. Test: Growing usage of IGRA in diagnosing latent TB infection due to their non-invasive nature and effectiveness
  • 5.2.2. End User: High accessibility to tuberculosis testing through government and public health organizations to curb the spread of TB and achieve public health goals
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Tuberculosis Testing Market, by Test

• 6.1. Introduction
• 6.2. Culture-Based Tests
• 6.3. Interferon-Gamma Release Assays
• 6.4. Mantoux Tuberculin Skin Test
• 6.5. Nucleic Acid Amplification Tests
• 6.6. Smear Microscopy

7. Tuberculosis Testing Market, by Indication

• 7.1. Introduction
• 7.2. Active TB Infection
• 7.3. Latent TB Infection

8. Tuberculosis Testing Market, by Testing Location

• 8.1. Introduction
• 8.2. In-laboratory Testing
• 8.3. Point-of-Care Testing

9. Tuberculosis Testing Market, by End User

• 9.1. Introduction
• 9.2. Diagnostic Laboratories
• 9.3. Government & Public Health Organizations
• 9.4. Hospital
• 9.5. Research & Academic Institutions

10. Americas Tuberculosis Testing Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Tuberculosis Testing Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Tuberculosis Testing Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Revvity Introduces Advanced Automation for Tuberculosis Testing, Enhancing Efficiency and Accuracy
  • 13.3.2. MedGenome Collaborates with Darshan GIVA Foundation to Enhance TB Diagnosis through Whole Genome Sequencing
  • 13.3.3. VinBrain Partners with Vietnam's National TB Screening Initiative to Combat Tuberculosis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Becton, Dickinson, and Company
• 3. Bio-Rad Laboratories, Inc.
• 4. bioMerieux SA
• 5. Bruker Corporation
• 6. Cepheid by Danaher Corporation
• 7. Elisabeth Pharmacon, spol. s r.o.
• 8. ELITech Group SAS
• 9. F. Hoffmann-La Roche AG
• 10. Fujifilm Holdings Corporation
• 11. Hologic Corporation
• 12. Lionex Diagnostics & Therapeutics GmbH
• 13. OSANG HEALTHCARE CO., LTD
• 14. PerkinElmer, Inc.
• 15. SD Biosensor, INC.
• 16. Siemens AG
• 17. Thermo Fisher Scientific, Inc.
• 18. Trivitron Healthcare Private Limited
• 19. Tulip Diagnostics (P) Ltd
• 20. Turklab A.S.